Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcome evaluations in gout.
Schumacher HR, Taylor W, Joseph-Ridge N, Perez-Ruiz F, Chen LX, Schlesinger N, Khanna D, Furst DE, Becker MA, Dalbeth N, Edwards NL. Schumacher HR, et al. Among authors: joseph ridge n. J Rheumatol. 2007 Jun;34(6):1381-5. J Rheumatol. 2007. PMID: 17552064
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N. Schumacher HR Jr, et al. Among authors: joseph ridge n. Arthritis Rheum. 2008 Nov 15;59(11):1540-8. doi: 10.1002/art.24209. Arthritis Rheum. 2008. PMID: 18975369 Free article. Clinical Trial.
Outcome measures for acute and chronic gout.
Schumacher HR Jr, Edwards LN, Perez-Ruiz F, Becker M, Chen LX, Furst DE, Joseph-Ridge N, Schlesinger N, Horowitz Z, Saag K, Boice JA, Yamanaka H; OMERACT 7 Special Interest Group. Schumacher HR Jr, et al. J Rheumatol. 2005 Dec;32(12):2452-5. J Rheumatol. 2005. PMID: 16331785 Review.
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Palo WA, Eustace D, Vernillet L, Joseph-Ridge N. Becker MA, et al. Arthritis Rheum. 2005 Mar;52(3):916-23. doi: 10.1002/art.20935. Arthritis Rheum. 2005. PMID: 15751090 Free article. Clinical Trial.
24 results